[go: up one dir, main page]

WO2001097750A2 - Procede de fabrication d'un produit antiviral - Google Patents

Procede de fabrication d'un produit antiviral Download PDF

Info

Publication number
WO2001097750A2
WO2001097750A2 PCT/RU2001/000255 RU0100255W WO0197750A2 WO 2001097750 A2 WO2001097750 A2 WO 2001097750A2 RU 0100255 W RU0100255 W RU 0100255W WO 0197750 A2 WO0197750 A2 WO 0197750A2
Authority
WO
WIPO (PCT)
Prior art keywords
lignin
producing
hours
antiviral agent
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2001/000255
Other languages
English (en)
Russian (ru)
Other versions
WO2001097750A3 (fr
Inventor
Valery Pavlovich Shipov
Evgeny Sergeevich Pigarev
Aleksandr Ivanovich Popov
Viktor Nikolaevich Ivanov
Galina Sergeevna Shitikova
Valery Afanasievich Trofimov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TROFIMOVA NADEZHDA VASILIEVNA
Nobel LLC
Original Assignee
TROFIMOVA NADEZHDA VASILIEVNA
Nobel LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TROFIMOVA NADEZHDA VASILIEVNA, Nobel LLC filed Critical TROFIMOVA NADEZHDA VASILIEVNA
Priority to AU2001277823A priority Critical patent/AU2001277823A1/en
Publication of WO2001097750A2 publication Critical patent/WO2001097750A2/fr
Publication of WO2001097750A3 publication Critical patent/WO2001097750A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the proposed invention is subject to biotechnology and may be used in the process of receiving electronic products from a wide range of products.
  • the closest to the claimed method is the method of receiving ⁇ iv ⁇ vi ⁇ usn ⁇ g ⁇ s ⁇ eds ⁇ va, in ⁇ isanny ( ⁇ , ⁇ TS, 93037252) ⁇ y ⁇ edusma ⁇ ivae ⁇ ⁇ b ⁇ ab ⁇ u ⁇ la ⁇ inida ⁇ aliya amm ⁇ niev ⁇ y s ⁇ lyu ⁇ a ⁇ b ⁇ n ⁇ v ⁇ y ⁇ isl ⁇ y, ⁇ i e ⁇ m in ⁇ aches ⁇ ve amm ⁇ niev ⁇ y s ⁇ li is ⁇ lzuyu ⁇ lign ⁇ -gumin ⁇ vye s ⁇ li ⁇ a ⁇ b ⁇ n ⁇ v ⁇ y ⁇ isl ⁇ y, ⁇ ye ⁇ edva ⁇ i ⁇ eln ⁇ sin ⁇ ezi ⁇ uyu ⁇ ⁇ isleniem lignin schel ⁇ chn ⁇ y s ⁇ ede with ⁇ sleduyuschim release lign ⁇ - humic acid and ammonia neutral
  • the objective of the proposed invention is to dispose of a product from a raw material to a product that is beneficial to the consumer.
  • P ⁇ s ⁇ avlennaya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ ⁇ edl ⁇ zhen s ⁇ s ⁇ b ⁇ lucheniya ⁇ iv ⁇ vi ⁇ usn ⁇ g ⁇ s ⁇ eds ⁇ va, ⁇ edusma ⁇ ivayuschy ⁇ b ⁇ ab ⁇ u ⁇ la ⁇ inida ⁇ aliya ⁇ d deys ⁇ viem ul ⁇ azvu ⁇ a in ⁇ ezhime ⁇ azvi ⁇ y a ⁇ us ⁇ iches ⁇ y ⁇ avi ⁇ atsii amm ⁇ niev ⁇ y s ⁇ lyu lign ⁇ -gumin ⁇ vy ⁇ ⁇ a ⁇ b ⁇ n ⁇ vy ⁇ ⁇ isl ⁇ , ⁇ luchenny ⁇ ⁇ isleniem lignin schel ⁇ chn ⁇ y s ⁇ ede, ⁇ i e ⁇ m in s ⁇ ve ⁇ s ⁇ vii with iz ⁇ b ⁇ e ⁇ enie
  • the acidification of medical lignin in an alkaline environment can be handled at a temperature of 150-170 ° ⁇ .
  • the pressure in the process separates the partial pressure of the acid in the processed product, which affects the rate of oxidation.
  • viruses of the first group of the 1st and 2nd series have been carried out after an initial evaluation of the toxicity of the equipment for the indicated culture of the cells. For example, dilutions of the preparation were used, which amounted to 1/2 of its minimum toxic dose and were accepted for the working dose of the preparation.
  • composition of the suspension is a mixture of the suspension:
  • Suspension density 1 9 Acidification is carried out in a process with mechanical stirring at a temperature of 160 ⁇ 5 ° ⁇ at a pressure of 2.5 ⁇ réelleice Pa for 1 hour. The air intake was 5 l / min.
  • the resulting solution was produced at 0.17-0.27 mass. % platinum potassium per 1 g of humic acid and create The process of developing acoustic cavitation by deactivating ultrasound with an output power of 40 W / cm and a frequency of 22 kHz for 1 min. Further, the volume of the product is up to 100 ml.
  • the potent activity of the proposed remedy in the case of a viral load of the 1st plant is established more than 10 times lower than in the condition of the condition P ⁇ iv ⁇ vy ⁇ usnaya a ⁇ ivn ⁇ s ⁇ izves ⁇ n ⁇ g ⁇ ⁇ iv ⁇ vi ⁇ usn ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a " ⁇ eman ⁇ adin" (sin ⁇ nimy " ⁇ ta ⁇ as ⁇ e", ' ⁇ -126 ") ⁇ -1- ⁇ e ⁇ il adaman ⁇ il- me ⁇ ilamin gid ⁇ l ⁇ id in ⁇ avny ⁇ usl ⁇ viya ⁇ in ⁇ n ⁇ shenii ⁇ vi ⁇ usam ge ⁇ esa s ⁇ s ⁇ avila 1,0-1,5 1 ⁇ ⁇ TSD 5 ⁇ / ml and its concentration in the culture liquid equal to 0.125 mg / ml (working dose).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Le procédé de fabrication d'un produit antiviral de l'invention consiste à traiter un platinide de sodium avec du sel d'ammonium de l'acide carbonique; on utilise à cet effet des acides humiques obtenus à partir de la lignine oxydée à usage médical, que l'on fabrique par l'oxydation de la lignine oxydée avec de l'oxygène contenu dans l'air, dans un milieu aqueux de base à une température entre 150 DEG et 170 DEG C et une pression entre 2,0 et 2,5 MPa pendant 0,5 heure à 1,5 heure. La préparation ainsi obtenue manifeste une activité antivirale fortement prononcée dirigée contre les virus de l'herpès simple des sérotypes 1 et 2, de la grippe et du sarcome de Rous.
PCT/RU2001/000255 2000-06-19 2001-06-15 Procede de fabrication d'un produit antiviral Ceased WO2001097750A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277823A AU2001277823A1 (en) 2000-06-19 2001-06-15 Method for producing an antiviral agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2000115399/14A RU2172176C1 (ru) 2000-06-19 2000-06-19 Способ получения противовирусного средства
RU2000115399 2000-06-19

Publications (2)

Publication Number Publication Date
WO2001097750A2 true WO2001097750A2 (fr) 2001-12-27
WO2001097750A3 WO2001097750A3 (fr) 2002-03-07

Family

ID=20236225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2001/000255 Ceased WO2001097750A2 (fr) 2000-06-19 2001-06-15 Procede de fabrication d'un produit antiviral

Country Status (3)

Country Link
AU (1) AU2001277823A1 (fr)
RU (1) RU2172176C1 (fr)
WO (1) WO2001097750A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369122A4 (fr) * 2001-02-21 2004-05-06 Nobel Ltd Liability Company Agent anticancereux
WO2013143549A1 (fr) * 2012-03-30 2013-10-03 Rdinnovation Aps Composés acides benzène polycarboxyliques et leur utilisation comme médicament

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678986C1 (ru) * 2018-03-23 2019-02-05 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противовирусное средство на основе гуминовых кислот

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419351A (en) * 1977-06-03 1983-12-06 Research Corporation Platinum-dioxopyrimidine complexes
US4873226A (en) * 1983-06-17 1989-10-10 Delta Metals, Inc. Method of inhibiting herpetic lesions by the use of platinum coordination compounds
DE4017091A1 (de) * 1990-05-27 1991-11-28 Walter Dr Mach Molekuelverbundsystem zur kontra-eskalativen therapie viraler infektionskrankheiten

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369122A4 (fr) * 2001-02-21 2004-05-06 Nobel Ltd Liability Company Agent anticancereux
EP1810684A3 (fr) * 2001-02-21 2008-04-16 Nobel Limited Liability Company Agent anticancéreux
WO2013143549A1 (fr) * 2012-03-30 2013-10-03 Rdinnovation Aps Composés acides benzène polycarboxyliques et leur utilisation comme médicament
CN104245800A (zh) * 2012-03-30 2014-12-24 Rd创新有限公司 新苯聚羧酸化合物
US9644074B2 (en) 2012-03-30 2017-05-09 Rinnovation Aps Benzene polycarboxylic acid compounds and their use as drug

Also Published As

Publication number Publication date
RU2172176C1 (ru) 2001-08-20
AU2001277823A1 (en) 2002-01-02
WO2001097750A3 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
Ley Jr et al. On the isolation from agar of an inhibitor for Neisseria gonorrhoeae
CN102153672B (zh) 一种硫酸软骨素的提取方法
CN107722138A (zh) 一种甲壳素制备水溶性羧甲基壳聚糖的新方法
CN105481044A (zh) 一种高效污水处理片剂及其制备方法
EA006435B1 (ru) Способ получения пищевой добавки, добавка и ее применение
CN104311628A (zh) 一种蛋白溶液细菌内毒素去除方法
WO2001097750A2 (fr) Procede de fabrication d'un produit antiviral
RU1809765C (ru) Способ получени противовирусного средства
WO1989012689A1 (fr) Procede pour obtenir un melange de ribonucleotides
CN108610434A (zh) 褐藻多糖硫酸酯环保提取纯化方法
CN108484630A (zh) 一种盐霉素提纯方法
JPH03206043A (ja) ウイルス感染防止剤
CN1032170A (zh) 由松子外壳中提取生理活性物质的方法和以该提取物为主要粗材料制备的抗传染病药物
WO2002024610A2 (fr) Procede de production d'un antineoplasique
JPS6357507A (ja) 化粧品原料の製造方法
RU2038095C1 (ru) Способ получения глюкозамина гидрохлорида, обладающего противоартрозной активностью
WO2008054247A1 (fr) Procédé de production d'un immunomodulateur apyrogénique
RU2017751C1 (ru) Способ получения гиалуроновой кислоты
RU2266915C1 (ru) Способ получения полиэтиленгликолевого эфира хитозана
WO1996009832A1 (fr) Hybride d'adn-arn et preparation d'adn, procedes d'obtention dudit hybride et de ladite preparation a partir de laitance d'esturgeon, et compose pharmaceutique a base dudit hybride d'adn-arn
KR20110056346A (ko) 고순도의 의료용 히아루론산의 제조 방법
CN1035051A (zh) 一种新型药物茯苓素的制造方法
EP1338281A1 (fr) Procede de fabrication d'un produit antiviral immunotropique
RU2828278C1 (ru) Способ получения биологически активной добавки из гонад гидробионтов
JPH05295328A (ja) プロポリス抽出液

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BG BR CA CN CZ DE DK EE ES FI GB GE HR HU IL IN IS JP KE KR KZ LT LV NO NZ PL PT SE SK TR UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BG BR CA CN CZ DE DK EE ES FI GB GE HR HU IL IN IS JP KE KR KZ LT LV NO NZ PL PT SE SK TR UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC.(EPO LETTER FORM 1205A HAS BEEN SENT ON 10/06/2003)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP